Furthermore, NAFLD patients exhibit impaired eNOS (endothelial NOS) function in systemic circulating platelets [194], which may further lead to reduced nitric oxide production and impair nitric oxide-dependent vasodilatation. The gene discussed is NOS3; the disease is metabolic dysfunction-associated steatotic liver disease.